Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.
RNA interference technology has been developed as a potential therapeutic agent for many indications, including cancer. Silencing a specific oncogene in tumor cells brings about cell death both in vitro and in vivo. However, there is a great need for powerful delivery strategies to enhance the therapeutic effect of small interfering RNA (siRNA). This review summarizes different signaling pathways inhibited by siRNA and the advantages of targeted siRNA as a delivery system.
Chen
Yunching
Y
University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Division of Molecular Pharmaceutics, Campus Box 7360 Kerr Hall, Chapel Hill, NC 27599, USA.
Huang
Leaf
L
D004337:Drug Carriers; D016503:Drug Delivery Systems / Q000379:methods*; D020868:Gene Silencing; D015316:Genetic Therapy; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics* / Q000494:pharmacology
D004337:Drug Carriers; D034741:RNA, Small Interfering